Steven Cohen’s X4 Pharmaceuticals XFOR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$192K Buy
+41,072
New +$169K ﹤0.01% 3555
2026
Q1
Sell
-808,154
Closed -$3.23M 4605
2025
Q4
$3.23M Buy
808,154
+786,488
+3,630% +$2.86M ﹤0.01% 2151
2025
Q3
$74.1K Sell
21,666
-1
-0% -$3 ﹤0.01% 2218
2025
Q2
$41.2K Hold
21,667
﹤0.01% 2111
2025
Q1
$154K Hold
21,667
﹤0.01% 1860
2024
Q4
$477K Buy
21,667
+832
+4% +$13.3K ﹤0.01% 1677
2024
Q3
$418K Buy
20,835
+2,732
+15% +$57K ﹤0.01% 1649
2024
Q2
$315K Sell
18,103
-3,564
-16% -$117K ﹤0.01% 1527
2024
Q1
$904K Hold
21,667
﹤0.01% 1484
2023
Q4
$545K Hold
21,667
﹤0.01% 1556
2023
Q3
$709K Hold
21,667
﹤0.01% 1433
2023
Q2
$1.26M Hold
21,667
﹤0.01% 1105
2023
Q1
$566K Hold
21,667
﹤0.01% 1210
2022
Q4
$645K Sell
21,667
-63,215
-74% -$2.99M ﹤0.01% 1113
2022
Q3
$4.35M Buy
84,882
+30,442
+56% +$1.05M 0.02% 761
2022
Q2
$1.58M Hold
54,440
0.01% 990
2022
Q1
$2.86M Hold
54,440
0.01% 818
2021
Q4
$3.74M Buy
+54,440
New +$6.89M 0.01% 729

Other funds holding XFOR

Steven Cohen's XFOR Position: Q2 2026 in Review

Steven Cohen opened a new position in X4 Pharmaceuticals (XFOR) in Q2 2026: 41,072 shares worth $192K. The stake represents ﹤0.01% of the portfolio and ranks #3555 among its holdings. This is a return to the name: Steven Cohen previously reported a position in XFOR as recently as Q4 2025.

Steven Cohen first reported a position in XFOR in Q4 2021 and has held it in 18 quarters since. The position peaked at $4.35M in Q3 2022. 88 funds tracked by Wall St. Rank hold XFOR as of Q2 2026.

  • Steven Cohen held 41,072 shares of X4 Pharmaceuticals worth $192K as of Q2 2026.
  • X4 Pharmaceuticals was a new Steven Cohen position in Q2 2026.
  • X4 Pharmaceuticals made up ﹤0.01% of Steven Cohen's portfolio in Q2 2026, its #3555 holding.
  • Steven Cohen first reported a position in X4 Pharmaceuticals in Q4 2021 and has held it in 18 quarters since.
  • Steven Cohen's X4 Pharmaceuticals position peaked at $4.35M in Q3 2022.
  • 88 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.